This is a randomized, open-label, controlled, Phase II proof of concept study to evaluate the safety, tolerability and efficacy of S-1226 in which hospitalized subjects (n≤30) with moderate severity COVID-19 Bronchiolitis/Pneumonia will be enrolled. The safety and tolerability of S-1226 composed of PFOB with ascending doses of carbon dioxide (4%, 8%, and 12% CO2) administered twice daily will be assessed subjects in hospitalized subjects with moderate severity COVID-19 Bronchiolitis/Pneumonia.
This is a randomized, open-label, controlled, Phase II proof of concept study to evaluate the
safety, tolerability and efficacy of S-1226 in which hospitalized subjects with moderate
severity COVID-19 Bronchiolitis/Pneumonia.
S-1226 contains a potent, safe and well-tolerated bronchodilator gas (extrinsic carbon
dioxide or CO2) and perflubron (PFOB), a synthetic surfactant that facilitates restoration of
surfactant function and mucus clearance. The inhaled S-1226 combination of gas, vapour and
liquid aerosol penetrates obstructed airways, resulting in rapid bronchodilation, enhanced
blood oxygenation, improved mucus clearance and reduction of work of breathing
The primary objective of this study is to evaluate the safety and tolerability of S-1226
composed of perflubron (PFOB) with ascending doses of carbon dioxide (4%, 8% and 12% CO2) in
hospitalized subjects with moderate severity COVID-19 bronchiolitis/pneumonia. The secondary
objective is to establish proof of concept that S-1226 is effective in restoring lung
function in hospitalized subjects with moderate severity COVID-19 bronchiolitis/pneumonia.
The study will consist of three parts: screening period, Dosing and evaluation, follow up
period.
1. During the screening period, subjects will undergo safety assessments and their
eligibility to participate will be confirmed. Eligible subjects will then be randomly
assigned to either the treatment arm (S-1226 + Standard of Care arm) or the
non-treatment arm (Standard of Care only).
2. The dosing and evaluation period will take place over 5 days of with two doses per day.
Subjects who are randomized to receive S-1226 will be started on a dose level of S-1226
(4%). If tolerated, subjects will progress from 4%, followed by 8%, and then 12%. The
highest tolerated dose will then be used for the remainder of the treatment period. All
doses incorporate 3mL PFOB and will be administered over a 3-4 minute treatment period.
Any enrolled subject randomized to receive S-1226 will not be required to interrupt any
SOC treatment which includes supplementary oxygen.
Each S-1226 dose will be administered as inhaled gas & vapour using a Circulaire II
hybrid system specifically adapted with the addition of an absolute aerosol filter
installed at the site of aerosol generation. This filter removes all perflubron aerosol
so that in this trial the S-1226 Gaseous Delivery System delivers an inhaled drug
comprising gas (CO2 in air) and vapour (perflubron). In addition, the S-1226 Gaseous
Delivery System includes a high efficiency bacterial/viral filter to scavenge any
patient-generated exhaled aerosol.
3. Follow up Period will 28 days after the first dose of S1226 has been administered.
Drug: S-1226
S-1226 has two components delivered by inhalation. It is a mixture of perfluorooctylbromide (PFOB) delivered in vapour form within a medical gas mixture containing CO2. The PFOB component remains the same but the medical gas component contains 4%, 8%, or 12% CO2
Other Name: Array
Inclusion Criteria:
- Subjects must meet the following criteria to be included in the study:
1. Male or Females between 18-80 years of age at the time of consent.
2. Laboratory-confirmed COVID-19 infection
3. Hospitalized for COVID-19 with clinical evidence of respiratory involvement,
including at least one of the following:
1. Symptoms/Signs: cough, respiratory distress, increased work of breathing
2. Radiology: Chest radiograph or other chest imaging demonstrating one of
bronchial thickening, increased secretions, hyperinflation, infiltrates
4. Hypoxemia in room air, SpO2 ≤ 90%
5. Patient belongs to one of the following two categories in the seven-point
COVID-19 severity scale:
1. Requiring supplemental oxygen by nasal prongs - Level 4 of the seven-point
COVID-19 severity scale;
2. Requiring nasal high-flow oxygen therapy,- limited to this one component of
Level 5 of the seven-point COVID-19 severity scale.
6. For women of childbearing potential involved in any sexual intercourse that could
lead to pregnancy: Negative pregnancy test and willingness to use contraceptive
(consistent with local regulations) during the study period.
7. Ability to sign informed consent or, when patient is not capable of doing so,
informed consent can be signed by legal/authorized representative
Exclusion Criteria:
- Subjects to whom any of the following applies will be excluded from the study:
1. Pregnant or breastfeeding females.
2. Patients unable to receive S-1226; particularly if receiving oxygen therapy by
face mask or non invasive ventilatory support
3. Patient requires Extracorporeal Membrane Oxygenation (ECMO) and/or invasive
mechanical ventilation
4. Presence of any of the following abnormal laboratory values at screening:
1. Absolute neutrophil count (ANC) less than 0.5 x 109 / L.
2. Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) greater than
5 x upper limit of normal (ULN).
3. Platelets less than 50 x109 / L.
5. In the opinion of the investigator, progression to death is imminent and
inevitable within the next 72 hours, irrespective of the provision of treatment.
6. Subject, who in the opinion of the Investigator, is unsuitable to participate
Alberta Lung Function
Calgary, Alberta, Canada
Mark Montgomery, MD, Principal Investigator
University of Calgary